HUANGSHAN-TOURISM
14.3.2022 12:38:06 CET | Business Wire | Press release
Huangshan again captured the imagination of guests at the 2022 ITB Berlin, the world's largest travel trade fair. This year’s virtual ITB Berlin, held from March 8 to 10, saw experts and industry representatives from around the world explore and discuss digital, resilient, and responsible solutions for the global tourism industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220314005401/en/
At the event, Huangshan Tourism Development Co., Ltd. (Huangshan Tourism) held a press conference and multimedia presentation to showcase the many attractions of Huangshan, including its prime location, unique landscapes, rich cultural heritage, and well-developed infrastructures to support local tourism.
The presentation covered six highlights that make Huangshan so appealing as a travel destination.
“Travel in Huangshan” showed its access to a transport network connecting key travel hubs in China. “The Beauty of Huangshan” put the spotlight on the spectacular scenery of Huangshan, from mountain landscapes and its characteristic pine trees to the nearby Taiping Lake. “The Food of Huangshan” gave a taste of the local Huizhou cuisine, one of China’s eight major cuisines. "Accommodation in Huangshan" provided an overview of the high-standard international tourist lodging. “Gifts from Huangshan" gave a glimpse of the unique local presents. Finally, “Culture in Huangshan” introduced the audience to the rich range of cultural and creative products that embody the handicraft, heritage, and traditions of the region.
The immersive format of the event and images of Huangshan Mountain and surrounding areas left a striking visual impact on the audience, again stimulating interest in Huangshan as a world-class travel destination that epitomizes the very best of China’s natural beauty and rich cultural heritage.
About Huangshan Tourism
Huangshan Tourism is one of China’s leading listed tourism companies. It covers a wide scope of business in and around the Mount Huangshan Scenic Area in China’s Anhui Province, from scenic spots and hotels to retail, catering, travel agencies, rural tourism, and other services.
Huangshan Tourism is committed to telling the story of Huangshan, Huizhou culture, and promoting the area as a top destination for both domestic and international tourists. The company carries out extensive overseas publicity and promotional activities, with over 150,000 followers across Facebook, Twitter, and Instagram. On New Year’s Day and during the Spring Festival this year, Huangshan Tourism once again caught the attention of global audiences with activities in Times Square in New York and Trafalgar Square in London.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005401/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom